Non-Invasive Continuous Glucose Monitoring Patch GlucoSkin Receives CE Certification: Real-Time Blood Sugar Monitoring via Interstitial Fluid Without Finger Pricks

On June 28, 2029, Germany's BioSense announced that its non-invasive continuous glucose monitoring patch GlucoSkin received CE certification in the European Union. The coin-sized patch, worn on the inner upper arm, uses reverse iontophoresis to extract trace glucose from skin interstitial fluid, updating blood sugar readings every 5 minutes without any finger pricks.

GlucoSkin uses low-intensity electrical current (imperceptible to users) to stimulate the skin surface, causing glucose in interstitial fluid to permeate to the biosensor on the patch surface. The built-in AI calibration algorithm compensates for the time lag between interstitial fluid glucose and blood glucose (typically 5-15 minutes), achieving a mean absolute relative difference (MARD) of 9.2% against fingertip blood glucose in clinical trials.

"There are 537 million diabetes patients worldwide, most needing to prick their fingers 2-4 times daily," said BioSense CEO Friedrich Weber. "GlucoSkin eliminates that pain and inconvenience." Each patch lasts 14 days and costs approximately €40.

Existing CGM products like Abbott's FreeStyle Libre and Dexcom's G7 still require minimally invasive sensor implantation. GlucoSkin's non-invasive nature is its core differentiator. However, the 9.2% MARD is slightly higher than FreeStyle Libre 3's 7.9%, with some precision gap remaining in low blood sugar warning accuracy.